Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
Excerpt:
In all assays, sensitivity to PD173074, AZ8010 or AZD4547 was confined to those cells...the absence of deregulated FGFR (MM.1S) or the presence of NRASG13N (H929) was associated with resistance to FGFRi.